Mogitate M. Epipharynegal Abrasive Therapy Downregulates the Number of Epipharyngeal Abrasive CD4 Cells With Symptomatic Recovery.
Cureus 2023;
15:e50288. [PMID:
38089949 PMCID:
PMC10710962 DOI:
10.7759/cureus.50288]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2023] [Indexed: 09/26/2024] Open
Abstract
OBJECTIVE
In this study, the author focused on CD4 and CD8 profiles in epipharyngeal abrasive cells in patients with chronic epipharyngitis and investigated how the profiles differ from those in normal healthy subjects and how epipharyngeal abrasive therapy (EAT) influences these profiles.
METHODS
This study included 18 patients (one male and 17 females, median age: 46 (30.0-56.5) years) who had been treated for chronic epipharyngitis between June 2021 and September 2021. Epipharyngeal abrasive cells were collected from patients with chronic epipharyngitis before EAT and three months after repeated EAT and were subjected to two-color flow cytometric analyses for CD4 and CD8 expression. The severity of participants' symptoms was monitored using the visual analog scale.
RESULTS
Symptoms of chronic epipharyngitis were significantly abated after three months of repeated EAT (p <0.001). The number of epipharyngeal abrasive CD4(+) T cells in patients with chronic epipharyngitis before EAT, which was significantly higher than that in normal healthy subjects (p <0.01), significantly decreased by the third month of repeated EAT (p = 0.01), alongside symptomatic recovery.
CONCLUSION
These results suggest that epipharyngeal CD4(+) T cells may have a critical role in treating the persistent inflammation of chronic epipharyngitis, and EAT may reduce the number of CD4 cells, which results in symptomatic recovery.
Collapse